IUPAC/Chemical Name
6,6'-Dichlor-2,2'-methylendithymol
InChi Key
HNOOXWDWUSLXOB-UHFFFAOYSA-N
InChi Code
InChI=1S/C21H26Cl2O2/c1-10(2)14-8-18(22)12(5)16(20(14)24)7-17-13(6)19(23)9-15(11(3)4)21(17)25/h8-11,24-25H,7H2,1-6H3
SMILES Code
CC1=C(CC(C(O)=C(C(C)C)C=C2Cl)=C2C)C(O)=C(C(C)C)C=C1Cl
Purity
>98% (or refer to the Certificate of Analysis)
Shipping Condition
Shipped under ambient temperature as non-hazardous chemical. This product is stable enough for a few weeks during ordinary shipping and time spent in Customs.
Storage Condition
Dry, dark and at 0 - 4 C for short term (days to weeks) or -20 C for long term (months to years).
Solubility
Soluble in DMSO
Shelf Life
>2 years if stored properly
Drug Formulation
This drug may be formulated in DMSO
Stock Solution Storage
0 - 4 C for short term (days to weeks), or -20 C for long term (months).
HS Tariff Code
2934.99.9001
Preparing Stock Solutions
The following data is based on the
product
molecular weight
381.34
Batch specific molecular weights may vary
from batch to batch
due to the degree of hydration, which will
affect the solvent
volumes required to prepare stock solutions.
| Concentration / Solvent Volume / Mass |
1 mg |
5 mg |
10 mg |
| 1 mM |
1.15 mL |
5.76 mL |
11.51 mL |
| 5 mM |
0.23 mL |
1.15 mL |
2.3 mL |
| 10 mM |
0.12 mL |
0.58 mL |
1.15 mL |
| 50 mM |
0.02 mL |
0.12 mL |
0.23 mL |
1: Schammé B, Couvrat N, Malpeli P, Delbreilh L, Dupray V, Dargent É, Coquerel G. Crystallization kinetics and molecular mobility of an amorphous active pharmaceutical ingredient: A case study with Biclotymol. Int J Pharm. 2015 Jul 25;490(1-2):248-57. doi: 10.1016/j.ijpharm.2015.05.036. Epub 2015 May 21. PubMed PMID: 26003417.
2: Tripathi P, Romanini M, Tamarit JL, Macovez R. Collective relaxation dynamics and crystallization kinetics of the amorphous Biclotymol antiseptic. Int J Pharm. 2015 Nov 10;495(1):420-7. doi: 10.1016/j.ijpharm.2015.09.012. Epub 2015 Sep 10. PubMed PMID: 26364713.
3: Schammé B, Couvrat N, Malpeli P, Dudognon E, Delbreilh L, Dupray V, Dargent É, Coquerel G. Transformation of an active pharmaceutical ingredient upon high-energy milling: A process-induced disorder in Biclotymol. Int J Pharm. 2016 Feb 29;499(1-2):67-73. doi: 10.1016/j.ijpharm.2015.12.032. Epub 2015 Dec 17. PubMed PMID: 26707413.
4: Céolin R, Tamarit JL, Barrio M, López DO, Nicolaï B, Veglio N, Perrin MA, Espeau P. Overall monotropic behavior of a metastable phase of biclotymol, 2,2'-methylenebis(4-chloro-3-methyl-isopropylphenol), inferred from experimental and topological construction of the related P-T state diagram. J Pharm Sci. 2008 Sep;97(9):3927-41. doi: 10.1002/jps.21285. PubMed PMID: 18200530.
5: Charfi O, Lakhoua G, Sahnoun R, Badri T, Daghfous R, El Aidli S, Kastalli S, Zaïem A. DRESS Syndrome Following Levofloxacin Exposure With Positive Patch-test. Therapie. 2015 Nov-Dec;70(6):547-9. doi: 10.2515/therapie/2015046. Epub 2015 Aug 3. Review. PubMed PMID: 26238129.
6: Karpova E, Giacomelli L, Tumietto F. Role of biclotymol-based products in the treatment of infectious sore throat. Eur Rev Med Pharmacol Sci. 2017 Aug;21(16):3736-3743. PubMed PMID: 28925466.
